|
|
|
| home > white papers > Key to Outsourcing Method Development and Validation A Pragmatic Approach - RSSL |
|
|
 WHITE PAPERS |
|
RSSL
|
+44 (0)118 918 4024
|
|
http://www.rssl.com
|
|
University of Reading, Whiteknights Rd, Reading, West Berkshire RG6 6LA
|
|
|
Key to Outsourcing Method Development and Validation A Pragmatic Approach
|
|
In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Peli BioThermal showcase CoolPall™ Flex and industry leading solutions at Temperature Control and Logistics Conference
Peli BioThermal, the global name in temperature-controlled packaging, is exhibiting its industry leading shipper systems, including its innovative CoolPall™ Flex, at the 19th Annual Cool Chain Temperature Control and Logistics conference.
More info >> |
|
 |
White Papers |
 |
|
Successfully managing the unique demands of cell therapy supply chains
PCI Pharma Services
Cell therapy professionals joined a specialist webinar by industry experts from PCI Clinical Services and TrakCel, addressing the unique complexity of an autologous therapy supply chain. Hosted by European Pharmaceutical Manufacturer magazine, the webinar was delivered by Rachel Griffiths, Associate Director, Technical Services, PCI Clinincal Services, and Dr. Matthew Lakelin, Vice President, Scientific Affairs and Business Development, TrakCel . Here, we present the white paper from that webinar event.
More info >> |
|
 |
Industry Events |
 |
BioTrinity 2020
28-29 April 2020, Digitally delivered
BioTrinity is a long-running and highly regarded two day life sciences conference that takes place in Central London from 28-29 April. BioTrinity focuses on partnering, investment and collaboration and aims to inspire growth and create opportunities for all who attend. The core delegate mix includes early-stage and emerging biotech, medtech and digital health companies, big pharma executives and life sciences investors.
More info >> |
|
|
|
